Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

131I-apamistmab

Radiopharmaceutical · Cytotoxic, directed at CD45 (PTPRC)

Phase 1 Most advanced trial
1 Registered trials

What is 131I-apamistmab?

131I-apamistamab is a radiolabeled monoclonal antibody construct in which the apamistamab antibody carries the radioactive isotope iodine-131. It is given by intravenous infusion, with the dose individualized to patient height and weight. It is studied in sickle cell disease due to hemoglobin S.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Iodine (131I) apamistamab
Drug type
Radiopharmaceutical
Targets
CD45 (PTPRC)
Mechanism
Cytotoxic, directed at CD45 (PTPRC)
Therapy area
Hematology
In trials of
ATNM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07015684 Phase 1 Sickling Disorder Due to Hemoglobin S Recruiting ATNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Sickling Disorder Due to Hemoglobin S

Other drugs acting on PTPRC

131I-apamistamab Phase 2/3 Iodine I 131 Apamistamab Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.